Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Transplant benefit

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    140 result(s) found for: Transplant benefit. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2011-005257-31 Sponsor Protocol Number: IM103-144 Start Date*: 2014-04-28
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Multi-Center, Randomized Conversion Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belatacept Administered to Pediatric Subjects with a Stable Renal Transplant Revised...
    Medical condition: Kidney Transplant
    Disease: Version SOC Term Classification Code Term Level
    21.0 10042613 - Surgical and medical procedures 10038533 Renal transplant PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012258-19 Sponsor Protocol Number: F506-CL-0403 Start Date*: 2011-03-09
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: A Multicentre, Open-label, Pharmacokinetic Study of Modigraf® (Tacrolimus granules) in de novo Paediatric Allograft Recipients.Estudio Abierto, Multicéntrico, Farmacocinético de Modigraf® (Tacróli...
    Medical condition: De novo allograft transplantation (liver, heart, kidney) in paediatric patients. Pacientes pediátricos que reciben un trasplante de aloinjerto de novo ( hígado, corazón y riñón)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10024716 Liver transplantation LLT
    13.1 10042613 - Surgical and medical procedures 10019314 Heart transplant PT
    13.1 10042613 - Surgical and medical procedures 10023438 Kidney transplant LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) DE (Completed) BE (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-002097-13 Sponsor Protocol Number: SI-05-RG-45 Start Date*: 2017-05-15
    Sponsor Name:Department of Cardiology, University Medical Centre Ljubljana
    Full Title: Comparison of modified-release and standard tacrolimus immunosuppression regimens in heart transplant recipients
    Medical condition: Tacrolimus is a potent immunosuppressant agent widely used for the prevention and treatment of rejection in heart transplant recipients. While tacrolimus is typically administered in two divided do...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000925-36 Sponsor Protocol Number: CCFZ533X2201 Start Date*: 2015-11-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month randomized, multiple dose, open-label, study evaluating safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of an anti-CD40 monoclonal antibody, CFZ533, in combi...
    Medical condition: acute rejection of renal transplant in de novo adult renal transplant patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000237-12 Sponsor Protocol Number: IM103-402 Start Date*: 2021-05-04
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a...
    Medical condition: Adolescent Renal Allografts
    Disease: Version SOC Term Classification Code Term Level
    21.0 10042613 - Surgical and medical procedures 10038533 Renal transplant PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002231-32 Sponsor Protocol Number: PMR-EC-1106 Start Date*: 2009-03-04
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED...
    Medical condition: RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED POST-TRANSPLANT) AND MMF WITH OR WITHOUT SIMULECT
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) HU (Completed) BE (Completed) CZ (Completed) IE (Completed) DE (Completed) FR (Completed) ES (Completed) GB (Completed) IT (Completed) SE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012259-21 Sponsor Protocol Number: F506-CL-0404 Start Date*: 2011-03-02
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: A Long-term, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in Paediatric Solid Allograft Recipients.Estudio abierto, no compar...
    Medical condition: Stable paediatric allograft recipients.Pacientes estables receptores de un aloinjerto
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050432 Prophylaxis against heart transplant rejection LLT
    12.1 10050434 Prophylaxis against liver transplant rejection LLT
    12.1 10050436 Prophylaxis against renal transplant rejection LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) BE (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001798-26 Sponsor Protocol Number: PROMETE Start Date*: 2014-02-12
    Sponsor Name:CHU DE POITIERS
    Full Title: A multicenter, open-label, Prospective, randomized parallel group Phase III study investigating the benefit on Renal function of a CNI-free regimen with MyfOrtic® (mycophenolate sodium) and Certica...
    Medical condition: Kidney transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003633-32 Sponsor Protocol Number: CERL080A2419 Start Date*: 2006-11-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, multi-center, parallel-group, open-label study to evaluate the therapeutical benefit of an initially intensified dosing regimen of Myfortic® vs. a standard dosing regimen of Myfortic...
    Medical condition: Prophylaxis of rejection in recipients of first or second cadaveric, living unrelated or living related kidney transplants
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) IT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001836-24 Sponsor Protocol Number: CCFZ533A2202 Start Date*: 2019-05-16
    Sponsor Name:Novartis Pharma AG
    Full Title: A 12-month, open-label, multicenter, randomized, safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) study of two regimens of anti-CD40 monoclonal antibody, CFZ533 vs. standard of care ...
    Medical condition: Liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10024715 Liver transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) HU (Prematurely Ended) FR (Completed) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002949-30 Sponsor Protocol Number: ATA129-EBV-302 Start Date*: 2020-07-17
    Sponsor Name:Atara Biotherapeutics, Inc.
    Full Title: Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative D...
    Medical condition: Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068349 Epstein-Barr virus associated lymphoproliferative disorder PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075146 Post transplant Epstein-Barr virus associated lymphoproliferative disorder LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003835-28 Sponsor Protocol Number: APHP210089 Start Date*: 2022-02-17
    Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS
    Full Title: Prevention of C. difficile infections with oral vancomycin in patients treated for allogeneic hematopoietic stem cell transplantation, a double-blind, randomized, placebo-controlled trial ” VANCALLO
    Medical condition: Patients hospitalized for an allogeneic hematopoietic stem cell transplant
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004865 10059044 Allogeneic peripheral hematopoietic stem cell transplant LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004540-23 Sponsor Protocol Number: CAEB071A2206 Start Date*: 2007-07-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral® in combination with Certican®, ...
    Medical condition: renal transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) IT (Completed) FR (Completed) BE (Completed) NL (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001325-33 Sponsor Protocol Number: CELLIMIN Start Date*: 2015-07-02
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation
    Medical condition: kidney transplant patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-002238-21 Sponsor Protocol Number: EFC12522 Start Date*: 2017-08-31
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination with Bortezomib (Velcade®), Lenalidomide (Revlimid®) and Dexamethasone ve...
    Medical condition: Plasma cell myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035226 Plasma cell myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) LT (Trial now transitioned) BE (Completed) ES (Ongoing) PT (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000043-31 Sponsor Protocol Number: 383 Start Date*: 2020-03-26
    Sponsor Name:Groupe Hospitalier Paris Saint-Joseph
    Full Title: Efficacy and tolerance of Liraglutide for weight loss in obese type 2 diabetic hemodialysis patients
    Medical condition: obese type 2 diabetic hemodialysis patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003635-31 Sponsor Protocol Number: IM103-008 Start Date*: 2005-12-12
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT). Revised Protocol 05 incorporating Protocol Amendments 13 (dated 10-Feb-2011)
    Medical condition: TRANSPLANTATION,NOS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) GB (Completed) CZ (Completed) IT (Completed) DE (Completed) ES (Completed) SE (Completed) HU (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2009-018083-94 Sponsor Protocol Number: IEO S513/110 Start Date*: 2010-07-29
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients with High-Risk Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppressio...
    Medical condition: High risk Hematologic Malignancies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024324 HLGT
    9.1 10025323 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002980-33 Sponsor Protocol Number: BGB-3111-302 Start Date*: 2017-02-21
    Sponsor Name:BeiGene Ltd. c/o BeiGene USA Inc.
    Full Title: A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström’s Macr...
    Medical condition: Subjects with Waldenström’s Macroglobulinemia (WM) who require therapy according to the consensus panel criteria from the 7th International Workshop on Waldenström’s Macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047801 Waldenstrom's macroglobulinaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) SE (Completed) ES (Completed) NL (Completed) PL (Completed) GR (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001361-18 Sponsor Protocol Number: CERL080ABE01 Start Date*: 2004-09-28
    Sponsor Name:Novartis Pharma N.V.
    Full Title: Conversion trial from Cellcept® (MMF) to myfortic® (enteric-coated MPA) in stable transplanted patients suffering from GI adverse events while on Cellcept® therapy.
    Medical condition: liver or kidney transplant - stable
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA